Emyr Bakker
Title
Cited by
Cited by
Year
The role of microenvironment and immunity in drug response in leukemia
E Bakker, M Qattan, L Mutti, C Demonacos, M Krstic-Demonacos
Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1863 (3), 414-426, 2016
622016
Anti-CTLA-4 therapy for malignant mesothelioma
A Guazzelli, E Bakker, M Krstic-Demonacos, MP Lisanti, F Sotgia, L Mutti
Immunotherapy 9 (3), 273-280, 2017
182017
BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment
A Guazzelli, P Meysami, E Bakker, C Demonacos, A Giordano, ...
International Journal of Molecular Sciences 20 (2), 429, 2019
162019
Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma
A Guazzelli, E Bakker, K Tian, C Demonacos, M Krstic-Demonacos, ...
Expert Opinion on Investigational Drugs 26 (8), 933-944, 2017
132017
Immunotherapy advances for mesothelioma treatment
E Bakker, A Guazzelli, F Ashtiani, C Demonacos, M Krstic-Demonacos, ...
Expert review of anticancer therapy 17 (9), 799-814, 2017
92017
Insight into glucocorticoid receptor signalling through interactome model analysis
E Bakker, K Tian, L Mutti, C Demonacos, JM Schwartz, ...
PLoS computational biology 13 (11), e1005825, 2017
62017
Current and prospective pharmacotherapies for the treatment of pleural mesothelioma
E Bakker, A Guazzelli, M Krstic-Demonacos, M Lisanti, F Sotgia, L Mutti
Expert Opinion on Orphan Drugs 5 (6), 455-465, 2017
62017
Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia
MY Qattan, EY Bakker, R Rajendran, DWC Chen, V Saha, J Liu, L Zeef, ...
PloS one 12 (6), e0178606, 2017
52017
p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification
K Tian, E Bakker, M Hussain, A Guazzelli, H Alhebshi, P Meysami, ...
Journal of translational medicine 16 (1), 282, 2018
42018
Antitumor effects of a recombinant baculovirus displaying anti-HER2 scFv expressing Apoptin in HER2 positive SK-BR-3 breast cancer cells
P Meysami, F Rezaei, SM Marashi, MM Amiri, E Bakker, T Mokhtari-Azad
Future Virology 14 (3), 139-152, 2019
22019
What can independent research for mesothelioma achieve to treat this orphan disease?
A Guazzelli, P Meysami, E Bakker, E Bonanni, C Demonacos, ...
Expert Opinion on Investigational Drugs 28 (8), 719-732, 2019
12019
The use of multi-omics data and approaches in breast cancer immunotherapy: a review
KL Leung, D Verma, YJ Azam, E Bakker
Future Oncology, 2020
2020
The Treatment of Malignant Pleural Mesothelioma: From the Current Standard to Novel Possible Therapeutic Strategies
E Bakker, A Guazzelli, C Demonacos, M Krstic-Demonacos, L Mutti
Malignant Pleural Mesothelioma, 117-136, 2019
2019
161PDKK1 stabilization as a new malignant pleural mesothelioma therapeutic avenue
A Guazzelli, E Bakker, F Sotgia, M Listanti, M Krstic-Demonacos, L Mutti
Annals of Oncology 28 (suppl_2), 2017
2017
Analysis of drug resistance and the role of the stem cell niche in leukaemia
EY Bakker
University of Salford, 2017
2017
The role of the microenvironment in acute lymphoblastic leukaemia drug response
M Qattan, E Bakker, R Rajendran, DWC Chen, V Saha, J Liu, L Zeef, ...
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 38, S46-S46, 2016
2016
Glucocorticoid receptor interactome
E Bakker, K Tian, J Andrews, C Demonacos, JM Schwartz, ...
Society for Endocrinology BES 2014 34, 2014
2014
Determinants of drug and microenvironment response in acute lymphoblastic leukaemia
M Qattan, DWC Chen, V Saha, JZ Liu, L Zeef, JM Schwartz, E Bakker, ...
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 34, S112-S112, 2014
2014
The system can't perform the operation now. Try again later.
Articles 1–18